Cargando…

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Xin, McDermott, David F., Michaelson, M. Dror
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656499/ https://www.ncbi.nlm.nih.gov/pubmed/31036769 http://dx.doi.org/10.1634/theoncologist.2019-0165

Ejemplares similares

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

Toward lentiviral vectors for antiangiogenic ocular gene therapy
por: Askou, Anne Louise, et al.
Publicado: (2023)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

Diclofenac Loaded Biodegradable Nanoparticles as Antitumoral and Antiangiogenic Therapy
por: Esteruelas, Gerard, et al.
Publicado: (2022)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
por: Comandone, Alessandro, et al.
Publicado: (2021)

Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?
por: Miller, Kathy D
Publicado: (2004)

Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
por: Li, Shu‐Jin, et al.
Publicado: (2021)

Antiangiogenic and Antitumor Effects of Trypanosoma cruzi Calreticulin
por: López, Nandy C., et al.
Publicado: (2010)

Photodynamic therapy – hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity
por: Plenagl, Nikola, et al.
Publicado: (2019)

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma
por: Chen, Zhuo, et al.
Publicado: (2015)

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
por: Jiménez-Valerio, Gabriela, et al.
Publicado: (2016)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

β-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer
por: Hu, Jiali, et al.
Publicado: (2021)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Cell surface expression of nucleolin mediates the antiangiogenic and antitumor activities of kallistatin
por: Huang, Xiao-Ping, et al.
Publicado: (2017)

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
por: Ceci, Claudia, et al.
Publicado: (2018)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multidrug-resistant breast cancer
por: You, You-Hong, et al.
Publicado: (2019)

CD4 T Cells and Their Role in Antitumor Immune Responses
por: Toes, René E.M., et al.
Publicado: (1999)

The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
por: Hu, Haoyue, et al.
Publicado: (2022)

Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway
por: West, Camilla, et al.
Publicado: (2017)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Conjugation of VEGFR1/R2-targeting peptide with gold nanoparticles to enhance antiangiogenic and antitumoral activity
por: Zanjanchi, Pegah, et al.
Publicado: (2022)

Antitumor and Antiangiogenic Activities of Curcumin in Cervical Cancer Xenografts in Nude Mice
por: Yoysungnoen-Chintana, Pornphrom, et al.
Publicado: (2014)

Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma
por: Li, Xin, et al.
Publicado: (2021)

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
por: Zhu, Yuxuan, et al.
Publicado: (2019)

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
por: Xue, Liting, et al.
Publicado: (2021)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

A Translational Perspective of a Deubiquitinase Inhibitor in Antitumor Immunity
por: Li, Yangyang, et al.
Publicado: (2016)

Inhibiting DNA methylation improves antitumor immunity in ovarian cancer
por: Chiappinelli, Katherine B., et al.
Publicado: (2022)

Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact
por: Federico, Piera, et al.
Publicado: (2022)

Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy
por: Raica, Marius, et al.
Publicado: (2010)

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
por: Torimura, Takuji, et al.
Publicado: (2016)

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma
por: Deniz, Baris, et al.
Publicado: (2018)

Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
por: Setrerrahmane, Sarra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e1on56vvbbeit4qnagrsjocu2h